Riociguat (BAY 63-2521) - CAS 625115-55-1
Riociguat, also known as BAY 63-2521, is a novel drug that is currently in clinical development by Bayer. It is a stimulator of soluble guanylate cyclase (sGC). At the moment Phase III clinical trials investigate the use of riociguat as a new approach to treat two forms of pulmonary hypertension (PH): chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). Riociguat constitutes the first drug of a novel class of sGC stimulators.
Catalog Number: A000103
CAS Number: 625115-55-1
PubChem Substance ID:350095697
Molecular Formula: C20H19FN8O2
Molecular Weight:422.4
Purity: ≥95%
* For research use only. Not for human or veterinary use.
Synonym
Synonyms | NA |
---|
Property
Molecular Formula: | C20H19FN8O2 |
---|---|
Molecular Weight | 422.4 |
Target: | Guanylate Cyclase |
Solubility | >17mg/mL in DMSO |
Purity | ≥95% |
Storage | Store at -20°C |
Computed Descriptor
InChI | InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26) |
---|---|
InChIKey | WXXSNCNJFUAIDG-UHFFFAOYSA-N |
SMILES | FC1=C(CN2C(N=CC=C3)=C3C(C4=NC(N)=C(N(C)C(OC)=O)C(N)=N4)=N2)C=CC=C1 |